RT Book, Section
A1 Katzung, Bertram G.
A1 Kruidering-Hall, Marieke
A1 Tuan, Rupa Lalchandani
A1 Vanderah, Todd W.
A1 Trevor, Anthony J.
SR Print(0)
ID 1180559343
T1 Cannabinoid Drugs
T2 Katzung & Trevor's Pharmacology: Examination & Board Review, 13e
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260117127
LK accesspharmacy.mhmedical.com/content.aspx?aid=1180559343
RD 2024/04/18
AB Currently  available  cannabinoid  drugs  consist  of  one  major  subgroup  that  act  at  the  CB1  receptors.  However,  there  are  rapidly  developing  alternative  groups  of  drugs  that  target  newly  discovered  receptors  as  well  as  new  drugs  that  are  designed  to  enrich  endogenous  cannabinoids.Delta-9-tetrahydrocannabinol  (THC)  may  be  considered  the  prototype  that  acts  directly  at  both  CB1  and  CB2  receptors.  However,  THC  has  made  little  progress  in  clinical  use  due  to  the  psychoactive  component,  which  is  thought  to  be  due  mainly  to  action  at  the  CB1  receptor.  Novel  cannabinoids  are  being  discovered  that  lack  this  unwanted  (in  clinical  usage)  effect.